Enzymatic studies on the liver of an infant are described-a case of hypertyrosinemia without hepatic dysfunction. His parents were siblings and the mother had hypertyrosinemia. Excessive amounts of 4hydroxyphenylpyruvic acid (pHPP), 4-hydroxyphenylacetic acid (pHPL), and 4-hydroxyphenylacetic acid (pHPA) were found to be excreted in the patient's urine as well as in the urine of the mother and the inhibitor of porphobilinogen synthetase,was not found. Soluble tyrosine aminotransferase (s-TAT), separated from that of the mitochondrial form (m-TAT) by DE 52 column chromatography, was normal in the patient's liver, both quantitatively and qualitatively. The activities of fumarylacetoacetase in the liver and in the peripheral leucocytes from the parents were normal. The activity of pHPP oxidase in the patient's liver was approximately 5% of the control and the enzyme had a high
UV, ultk.aviolet
There are two types of hereditary tyrosinemia. Type I is characterized by liver and renal tubular dysfunctions (13, 21) , whereas type I1 is associated with mental retardation, eye and s k i lesions, and microcephalus (17, 21) . Patients belonging to either of these two types excrete a considerable amount of 4-hydroxyphenylpyruvic acid (pHPP), 4-hydroxyphenyllactic acid (pHPL) and 4-hydroxyphenylacetic acid (pHPA) in their urine (l7,21). Although it is thought to be a secondary defect (3) , pHPP oxidase in the liver was found to be reduced in type I patients (20) . Then, Lindblad et. al. (24) found that the type I patients excreted succinylacetone into their urine, which was probably derived from maleylacetoacetate or fumarylacetoacetate. They suggested that the fumarylacetoacetase was defective in the liver with this disease (24) . This view was confirmed by Fallstrom et. al. (10) . With regards to type 11, Fellman et. al, (1 1) clearly demonstrated the defective enzyme as being the soluble tyrosine aminotransferase (+TAT). Later reports also confirmed this fact (5, 22) .
We describe two cases of tyrosinemia, a male infant and his mother whose clinical and biochemical findings are distinct from those of hitherto reported types of hereditary tyrosinemia. CASE 
REPORT
Our patient was born at full-term after normal pregnancy and his birth weight was 4050 g. His parents were siblings. He was suffering from pneumonia and was admitted to a local hospital when he was 21 days old. At that time, he was also noted to have convulsions. The infection was treated with antibiotics but the neurologic findings did not improve. Hypertyrosinemia (21.6 mg/ dl) was found at the age of 29 days by the dry blood screening test, and was not improved by oral administration of vitamin C (500 mg/day). The infant was referred to the Department of Pediatrics, Kumamoto University Hospital at the age of 46 days for further investigation and treatment. On physical examination, the liver was palpable (0.5 cm under costal margin). Eyes and skin were normal. His consciousness was unclear and seizures resembling infantile spasms occurred several times per day. The background activity of the electroencephalogram was suppressed and single spike or polyspikes were observed on the left parietal or occipital areas. A brain CAT scan revealed mild brain atrophy. Normal laboratory values included peripheral blood counts, serum protein, bilirubin, phosphorus, calcium, and serum aspartate aminotransferase (GOT) and GPT activities. Urine analysis was normal except for the Milon test and 2,4-DNPH reaction, which were strongly positive. With an amino acid autoanalyzer, the patient's blood tyrosine level was 11.6 mg/dl, but other amino acid levels, including methionine, were normal. Increased amounts of serine, glycine, histidine, and tyrosine were excreted in his urine. After the administration of low phenylalanine and low tyrosine milk (30 mg/kg/day), the blood tyrosine level decreased to 1.5-2.1 mg/dl; however, the neurologic symptoms were not improved. When the tyrosine intake was increased to 100 mg/kg/ day, the blood tyrosine level also rose to 12.6 mg/dl. The blood tyrosine level was maintained around 10 mg/dl by administering 70 mg/kg/day of tyrosine and phenylalanine. At the age of 75 days, he was asphyxiated accidentally and died on the 105th day. During the clinical course, no evidence of liver dysfunction was observed. Histologic examination of the liver showed no hepatocellular damage other than mild fatty infiltration.
His father (24 years of age, elder brother of the mother) had a normal mental status and normal blood tyrosine level, whereas the mother (21 years of age) had mild mental retardation (IQ of approximately 80) and an elevated blood tyrosine level (6.1 mg/ dl). Their physical examinations were normal. Their routine laboratory studies, including liver function tests, were all normal except for the Milon test and 2,4-DNPH reaction of the mother's urine, which were positive. Another son of the mother (3 years of age), whose father was an unrelated person, was well developed. Informed consent was obtained from the parents for all the following investigations. (23) . Fumarylacetoacetate was prepared principally according to the procedure of Ravdin and Crandall(29) as follows: homogentisic acid oxidase was prepared from Wister strain rat liver according to the method of Edward and Knox (7) through step three. The enzyme was incubated with 1 mM of homogentisic acid at 37°C for 30 rnin in 10 mM of sodium carbonate, pH 6.0, under 95% O2 and 5% COz. The reaction was stopped by the addition of perchloric acid to a final concentration of 3%. The fumarylacetoacetate formed was purified by the method of Ravdin and Crandall (29) through the ether extraction method. The material obtained was stored at -70°C before use.
Anti-rat-tyrosine-transaminase-rabbit serum was kindly supplied by Dr. Towatari and Dr. Katunuma, Department of Enzyme Chemistry, Institute for Enzyme Research, Tokushima University Medical School.
Enzyme assay: Aspartate aminotransferase (GOT) was measured by the method of Karmen (16) . Mitochondria1 GOT (m-GOT) was measured after the elimination of the cytosolic-GOT (s-GOT) using a commercially available kit (Eiken Kagaku, Tokyo, Japan) as previously described (27) . Tyrosine aminotransferase (TAT) was measured by the method of Diamondstone (6) . The radiochemical assay of pHPP oxidase was carried out by the method of Lindblad (23) with slight modifications. The reaction mixture contained 0.1 mM I-[14C]-pHPP (0.02 pCi/assay), 10 mM reduced glutathione, 1.5 mM 2,6-dichlorophenolindophenol, 0.5 mM a,cul-dipyridyl, 15 mg/ml catalase, 0.1 M potassium phosphate buffer, pH 6.5 and an appropriate amount of the enzyme. The total amount of the reaction mixture was scaled down to 0.5 ml and the reaction time was 15 min, unless otherwise stated. The reaction was stopped by the addition of 1 ml of 0.5 M potassium monophosphate containing 30 mM diethyldithiocarbamic acid and the incubation was continued to collect [14C02] for 15 min.
Released 1 ' 4~0 2 1 during the incubation was collected in a piece of filter paper wh,ih contained 50 pl of ,8-phenethylamine 125% in ethanol, v/v). The radioactivity of the paper was counted by using Beckman Liquid Scintillation Counter. Fumarylacetoacetase wa: measured principally by the method of Edwards and Knox (8) 3s follows: the reaction mixture contained 0.1 M sodium phosp'late buffer, pH 7.5 and an appropriate amount of enzyme in a total volume of 0.495 ml. The mixture was preincubated in a cuvette, which was maintained at 37OC for 5 rnin and the reaction was started by the addition of 5 p1 of the substrate solution. A decrease of t3e optical density at 330 nm was recorded. The fmal substrate concsntration was 0.05 mM. The molecular extinction coefficient of fiimarylacetoacetate used was 13.5 x lo3. Porphobilinogen synthetase was assayed by the method of Collier (4) . The inhibition of porphobilinogen synthetase by urine was tested by the addition of urine samples into the reaction mixture at the start of the preincubation, according to the description of Gray et. al. (14) . Protein was measured by the method of Lowry et. al. (25) using bovine serum albumin as a standard.
Tissue preparation. The liver obtained after the autopsy was stored at -70°C before use. The frozen liver was homogenized by using a Potter-Elvejem glass-teflon homogenizer with the following different buffers: 10 mM potassium phosphate buffer, pH 7.4, was used for the assay of TAT; 0.1 M sodium phosphate buffer, pH 7.5, for the assay of fumarylacetoacetase; and 10 mM potassium phosphate buffer, pH 6.5, for the assay of pHPP oxidase.
Peripheral leucocytes were obtained by the modified method of Boyiim (2) . The cells were disrupted by the freezing and thawing method. Peripheral erythrocytes were prepared by washing the heparinized blood, and the packed cells were hemolyzed by the addition of ice cold water. The hemolysate was used as a source of porphobilinogen synthetase.
Separation of cytosolic TA T (s-TA T) of liver:
Because fractionation of soluble and mitochondrial fractions by centrifugation was impossible in the frozen liver, separation of s-TAT from mitochondrial TAT (m-TAT) was tested through a column chromatographic method. This method used frozen liver as well as fresh liver that was obtained by a surgical operation as reference material. The supernatant of frozen liver homogenate (10,000 X g for 30 min) was passed through a Sephadex G-25 column, which had been equilibrated with the same buffer. The eluate from the Sephadex G-25 column was applied to a DE 52 column (2 x 7 cm), which had been equilibrated with 10 mM potassium phosphate buffer, pH 7.4, and the column was washed with the same buffer. The unadsorbed fraction and the eluate were fractionated with a linear gradient of the buffer varying from 10-200 mM. In these fractionated solutions, the activities of GOT, m-GOT and TAT were measured. The same procedures were carried out in the soluble and mitochondrial fraction of the fresh liver.
Gas chromatography-mass spectrometry (GC/MS) analysis of urine samples. GC/MS analysis of urine samples were carried out as previously described (18) 
RESULTS
Chromatography of the soluble and mitochondrial fractions of the fresh control liver on DE 52 yielded three peaks in which the first corresponded to m-GOT and m-TAT, the second to s-GOT, and the third to s-TAT (Fig. la, b) . As is shown in Figure la , the second peak contained a weak activity of TAT. It was thought that s-GOT could transaminate tyrosine as well as aspartate. Chromatography of the supernatant (10,000 x g ) of the frozen liver from the patient as well as the control, yielded three similar peaks (Fig. lc, d) . The s-GOT in the second peak and the s-TAT in the third peak reacted to anti s-GOT serum and anti s-TAT serum respectively, similar to the fractions of the fresh liver. These results indicate that the fractionation procedure on DE 52 resulted in a clear separation of m-TAT and s-TAT, even in the frozen liver. The activity of s-TAT of the patient and control livers are summarized in Table 1 . Recovery rates of s-GOT and s-TAT from the DE 52 column were 85-89% and 76-86% respectively. Although s-TAT seemed to decrease in activity and as storage time (-70°C) increased, the patient's s-TAT activity was actually not different from that of the corresponding control. Apparent Km values of s-TAT for tyrosine and PALP were similar in the patient and the controls ( Table 1 ). The immunotitration curve of s-T i T using anti s-TAT serum showed similar profiles in the patieni and the controls (Fig. 2) .
In a preliminary study (9), the formation of homoge~iisic acid from pHPP was observed with the patient's liver homjgenate by the colorimetric method of Fellman et. al. (1 1) (20F of control) . In the present study, the pHPP oxidase was assayed by the method of Lindblad (23), which measured the released [14COz] from 1-['4C]-p~PP. Under the above described conditions, 25-35% of the substrate was oxidized by 25-75 pl of supernatant (of 10,000 X g) the control liver homogenate (10% w/v). The liver pHPP oxidase was found to be stable when stored at -70°C for at least 6 months. The enzyme activities of the patient and the controls are summarized in Table 2 . No inhibitor of the enzyme activity was found in the supernatant of the liver from the patient. Heat stability of pHPP oxidase at 47OC, 5 1 OC, and 54°C was similar in the controls and the patient. The ['4C02] production under different substrate concentrations was estimated in the patient and the control pHPP oxidase (Fig. 3a, b, c, d) , and from these figures, apparent Km values were calculated. As shown in Table 2 , the Km values for pHPP of the patient's enzyme was four times higher than those of the controls.
A visible UV spectrum of the purified fumarylacetoacetase indicated no contamination with the homogentisic acid, as was shown by Ravdin and Crandall (29) . The absorbance at 327 nm, corresponding to fumarylacetoacetate, decreased in the mixture after the addition of the supernatant of liver homogenate (10, 000 x g) as the incubation time increased. A similar reaction was observed when white blood cell lysate was substituted for the liver homogenate. A linear relationship was found between both the protein concentrations of the liver homogenate and leucocyte lysate to the reduction in fumarylacetoacetate. The enzyme, when kept below -70°C, was found to be stable for at least 6 months. Ninety-five percent of the liver enzyme existed in the soluble fraction and less than 5% in the mitochondria1 fraction. Therefore, almost all the fumarylacetoacetase in the supernatant of the frozen liver was of the soluble fraction. The enzyme activities of the patient's liver and that of the parents' white blood cells were within the normal range (Table 3) . Heat stability of the enzyme at 55°C was similar in the patient and the control livers (Tl,z, 5 min). The apparent Km values of the enzyme for fumarylacetoacetate were 2.5 pM in the controls and the patient's liver.
The inhibitor of porphobilinogen synthetase in the urin,: samples from the patient and his mother were examined at fasting and after tyrosine loading (100 mg/kg). No inhibiting activity was found in any of these samples.
As shown in Table 4 , the patient and his mother excreted highly elevated amounts of pHPP, pHPA, and pHPL, respectively.
DISCUSSION
In the present study, it was shown that DE 52 column chromatography is capable of separating s-TAT from m-TAT of the frozen liver. The m-TAT and s-TAT of the patient's liver were fractionated and found to be normal in activity. In addition, the elution profile on the chromatography, apparent Km values for tyrosine and for PALP, and immunotitration curve of s-TAT were similar in the patient and the control. These results indicated that the disease is not likely due to TAT deficiency.
Studies on fumarylacetoacetase in the patient's liver resulted in normal activity and normal parameters of the enzyme, such as heat stability and apparent Km value. The presence of fumarylacetoacetase in the white blood cells was clearly shown in the present study, which was supported by a recent report (19) . The observation is in conflict with the early report by Berger et. al. (1) . The normal activity in the patient's liver and in the parents' leucocytes may indicate that the fumarylacetoacetase is not the involved enzyme in our case.
With regard to pHPP oxidase, the enzyme in the patient's liver was 5% of the control activity, and had a high Km value for pHPP. There was no substance inhibiting pHPP oxidase in the patient's liver supernatant. These results suggest that the nature of the enzyme in the patient's liver is altered by structural gene mutation.
These observations conflict with hitherto reported tyrosinemia, because both pHPP oxidase and fumarylacetoacetase were impaired in the type I disease (although it is still unclear which is a primary defect) and only cytosol tyrosine aminotransferase in the type I1 disease. The absence of the inhibitor of porphobilinogen synthetase in the urine again conflicts with the type I disease (14, 24) ; thus, the case might be offered as a new variant form of tyrosinemia. The absence of hepatorenal insufficiency and ocu- The blood tyrosine levels of the patient and the mother are 12.6 mg/ dl and 6.0 mg/dl, respectively. 2Gaschromatographic peak area relative to international standard IS (18) . UD, undetectable.
lodermal lesions, which are typical clinical features of type I and type I1 disease (13, 17, 21) , respectively, also support this concept. The present case existed in a particular situation, because he was a product of siblings. If the disease is inherited with an autosomal recessive trait, the mother and her brother, the father of the patient, are likely to be homozygous and heterozygous, respectively, because mental retardation in association with elevated blood tyrosine and increased urinary pHPP, pHPA, and pHPL at fasting were found in the mother but not in the father. Another possible aspect is that the disease was inherited by Xlinked trait, where the mother in heterozygote and the patient hemizygote; however, inspecting the particular situation of the family, we preferred to consider that the disease was inherited as an autosomal recessive trait.
It is probable that, the mother's features are of pHPP oxidase deficiency. She excreted considerable amounts of pHPP, pHPL, and pHPA in her urine at which time the blood tyrosine level was 6.0 mg/dl (Table 4) . When tyrosine was administered to normal adults (100 mg/kg) the blood tyrosine level increased to 4.5-5.5 mg/dl, and only trace amounts of pHPP and pHPL and a small amount of pHPA were excreted. The excretion of these materials from the mother was less than that of the infant. It may be due to the difference of protein intake and blood tyrosine level (12.6 mg/ dl in the infant) between the infant and the mother. She had neither liver dysfunction nor abnormality of renal tubular function. The clinical and biochemical features resembled those of the case of Medes (28) . The inhibitor of porphobilinogen synthetase was absent in her urine and fumarvlacetoacetase in her leucocvtes was normal. These results differ f&m the usual type I tyrosineha (1, 13, 14, 15, 21, 24) . The elder brother of the patient, whose father was an unrelated person, was apparently normal at least until three years of age. Mild hypertyrosinemia, as observed in the mother, seemed to be harmless to the development of the fetus. Fellman et. al. (12) reported that the activity of pHPP oxidase in the human fetal liver and kidney was undetectable at least until 28 wk of gestational age; thus, maternal hypertyrosinemia and fetal pHPP oxidase deficiency, especially in the early or midfetal life of the fetus, might have no adverse effects on intrauterine development. On the other hand, the adverse effects of hypertyrosinemia had been observed in transient hypertyrosinemia of newborns (26) , although these effects were diminished with the reduction o f blood tyrosine level (26) .
In our case, the neurologic symptoms persisted even after the reduction of blood tyrosine level; therefore, these symptoms were not related to a high concentration of blood tyrosine level as observed in transient hypertyrosinemia of newborns. Although the mechanism of the development of neurologic symptoms is still unclear, it may have been augmented by the simultaneous presence of maternal and fetal hypertyrosinemia.
For a further understanding of the disease, the confirmation of the mutant enzyme in the mother remains to be established.
